Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up

BACKGROUND: The 21-gene recurrence score (RS) assay determines the benefit of adding chemotherapy to endocrine therapy for patients with early stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. The RS risk groups predict the likelihood of distant recurrence and have recently been a...

Descripción completa

Detalles Bibliográficos
Autores principales: Turashvili, Gulisa, Brogi, Edi, Morrow, Monica, Dickler, Maura, Norton, Larry, Hudis, Clifford, Wen, Hannah Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756373/
https://www.ncbi.nlm.nih.gov/pubmed/29304773
http://dx.doi.org/10.1186/s12885-017-3985-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756373/
https://www.ncbi.nlm.nih.gov/pubmed/29304773
http://dx.doi.org/10.1186/s12885-017-3985-y

Ejemplares similares